Advertisement

Advertisement

Breast Cancer

Intraoperative Margin Assessment in Breast-Conserving Surgery Using a Pegulicianine Fluorescence–Guided System

In the INSITE study reported in JAMA Surgery, E. Shelley Hwang, MD, MPH, and colleagues found that use of an intraoperative imaging agent with a pegulicianine fluorescence–guided system (pFGS) was effective in detecting residual cancer in the tumor bed of women with breast cancer undergoing...

Breast Cancer

Surgery Preference and Surgery Received in Women With DCIS

In an ancillary study of the ECOG-ACRIN Cancer Research Group E4112 study reported in JAMA Network Open, Fazeli et al found that patient preference of type of surgery and type of surgery received for ductal carcinoma in situ (DCIS) was influenced by preoperative magnetic resonance imaging (MRI)...

Gastrointestinal Cancer
Breast Cancer
Survivorship
Multiple Myeloma
Lymphoma

NCCN Clinical Practice Guidelines in Oncology: 2022 Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...

Breast Cancer

Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases

As reported in JAMA Oncology by Debu Tripathy, MD, and colleagues, the phase III ATTAIN trial has shown no difference in overall survival with etirinotecan pegol vs physician’s choice of chemotherapy for patients with metastatic breast cancer and brain metastases. As noted by the investigators,...

Breast Cancer

Study Investigates Possible Link Between Risk of Breast Cancer in Males and Male Infertility

The risk of invasive breast cancer in men may be associated with self-reported infertility, according to a study published by Swerdlow et al in the journal Breast Cancer Research. The authors interviewed 1,998 males in England and Wales diagnosed with breast cancer, with 112 (5.6%) also...

Breast Cancer

Do Electronic Health Interventions Improve Quality of Life and Other Health Outcomes in Patients With Breast Cancer?

In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Singleton et al found that electronic health interventions were associated with improved quality of life, distress, self-efficacy, and fatigue vs usual care during or after treatment in patients with breast...

Breast Cancer

Guideline-Concordant Treatment of Women in Sub-Saharan Africa With Nonmetastatic Breast Cancer

As reported in The Lancet Oncology by Foerster et al, the African Breast Cancer–Disparities in Outcomes prospective cohort study has shown that a high proportion of women in sub-Saharan Africa with newly diagnosed nonmetastatic breast cancer did not initiate, did not fully complete, or abandoned...

Breast Cancer

Sentinel Node May Not Be Informative in Making Treatment Decisions for Some Breast Cancer Subsets

In women aged 70 and older with hormone receptor–positive, HER2-negative, low-risk breast cancers, sentinel lymph node biopsy may not be a reliable indicator of the need for adjuvant chemotherapy, researchers reported at the 2022 American Society of Breast Surgeons Annual Meeting.1 “We found that...

Breast Cancer

Addition of Ibandronate to Adjuvant Endocrine Therapy in Postmenopausal Women With ER-Positive Breast Cancer

In the Dutch phase III TEAM-IIB trial reported in the Journal of Clinical Oncology, Sonja B. Vliek, MD, and colleagues found that the addition of oral ibandronate to adjuvant endocrine therapy did not improve disease-free survival in postmenopausal women with estrogen receptor (ER)-positive stage I ...

Breast Cancer

Why Are Black Women Still Dying at Higher Rates Than White Women From Breast Cancer?

What is so dismaying to me is that the statistic on survival for Black women with breast cancer has not changed since I was diagnosed with breast cancer 17 years ago. In 2005, Black women were 41% more likely to die of the disease than White women, even though Black women are less likely to be...

Breast Cancer

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...

Breast Cancer
Immunotherapy

TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases

In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...

Breast Cancer
Immunotherapy

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

On May 4, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. According to the approval, patients had to have received a prior anti-HER2–based regimen either in the...

Breast Cancer
Immunotherapy

Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...

Breast Cancer
Issues in Oncology

Case Study Examines Differences Between AI and Radiologist Perception in Breast Cancer Screening

Radiologists and artificial intelligence (AI) systems yield significant differences in breast cancer screenings, a team of researchers has found. The case study by Makino et al, which appears in the journal Nature Scientific Reports, reveals the potential value of using both human and AI methods in ...

Breast Cancer

Switch to Maintenance Endocrine Therapy Plus Bevacizumab After First-Line Paclitaxel/Bevacizumab Induction in Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer

In the Japanese phase II BOOSTER trial reported in The Lancet Oncology, Saji et al found that compared with continuing paclitaxel/bevacizumab, a maintenance strategy of switching to endocrine therapy plus bevacizumab (with the option of reinitiating paclitaxel/bevacizumab) was associated with a...

Breast Cancer

Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer

In a study reported in JAMA Surgery, Hanson et al found no difference in long-term satisfaction with breasts among women with early breast cancer who underwent breast-conserving surgery with radiation therapy vs mastectomy and breast reconstruction without radiation therapy. Women who underwent...

Breast Cancer

Preoperative Radiotherapy and DIEP Flap Reconstruction in Women Requiring Mastectomy for Breast Cancer

In the PRADA study—reported by Thiruchelvam et al in The Lancet Oncology—researchers found that a strategy of preoperative radiotherapy and deep inferior epigastric perforator (DIEP) flap reconstruction was feasible and safe in women requiring mastectomy for breast cancer. As stated by the...

gynecologic cancers
breast cancer
pancreatic cancer
prostate cancer
genomics/genetics

Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305

Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the PETRA study, a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2, or RAD51C/D mutations in advanced or metastatic ovarian cancer, HER2-negative breast cancer, pancreatic, or prostate cancer. Target engagement was demonstrated across all dose levels, and antitumor activity was observed in selected tumor and molecular subtypes.

Breast Cancer

Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports

Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...

Breast Cancer

New Study Examining Women’s Breast Density Knowledge Suggests Opportunities for Improvement

Breast density is one factor in assessing a person’s risk of developing breast cancer. Existing breast density notification laws have increased awareness among patients and providers, but clinical records had not been incorporated in studies to confirm the accuracy of personal breast density...

Breast Cancer

Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors

In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported...

Breast Cancer

Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for Triple-Negative Breast Cancer: The Paradigm Shifts

The “holy grail” of triple-negative breast cancer therapy has been effective incorporation of drugs to improve outcomes in the early nonmetastatic setting. Although outcomes have improved with better chemotherapy drugs and schedules, triple-negative breast cancer still carries the worst prognosis...

Breast Cancer
Immunotherapy

Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer

As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...

Breast Cancer

Phase III Trial Evaluates the Role of Aspirin in Preventing Breast Cancer Recurrence

Taking aspirin daily does not prevent breast cancer recurrence, according to research presented during the February ASCO Plenary Series Program.1 Results of the double-blind phase III study of more than 3,000 patients with high-risk, HER2-negative breast cancer showed no improvement in invasive...

Breast Cancer

New Factors That Can Predict Breast Cancer Recurrence Identified

Genetics and other factors that can determine if a woman is at risk for a recurrence of breast cancer have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing new research avenues for preventing a new tumor from developing. The discovery was made possible...

Breast Cancer

Is Neoadjuvant Pembrolizumab Underused in the Treatment of Early-Stage Triple-Negative Breast Cancer?

Neoadjuvant pembrolizumab has been approved in combination with chemotherapy for high-risk, early-stage, triple-negative breast cancer, but not all patients with node-positive disease have been able to receive the regimen, according to data presented during the Society of Surgical Oncology 2022...

Breast Cancer

Internal Mammary Node Irradiation in Node-Positive Early Breast Cancer: 15-Year Outcomes

As reported in the Journal of Clinical Oncology by Thorsen et al, 15-year follow-up of the Danish Breast Cancer Group Internal Mammary Node study indicates continued survival benefit with internal mammary node irradiation in women with right breast tumors vs without such therapy in those with left...

Breast Cancer

Role of 21-Gene Recurrence Score and Preoperative Endocrine Therapy Response in Guiding Treatment in Early Hormone Receptor–Positive, HER2-Negative Breast Cancer

In a German trial (WSG-ADAPT-HR1/HER2–) reported in the Journal of Clinical Oncology, Nitz et al found no difference in invasive disease-free survival between women with early hormone receptor–positive, HER2-negative breast cancer with zero to three positive nodes who had a 21-gene recurrence score ...

Breast Cancer

Breast Cancer Screening With Digital Breast Tomosynthesis Plus Synthesized Mammography vs Digital Mammography

In the German TOSYMA trial reported in The Lancet Oncology, Heindel et al found that screening with digital breast tomosynthesis plus synthesized mammography was superior in detecting invasive breast cancer vs standard digital mammography. As stated by the investigators, “Two-dimensional (2D)...

Breast Cancer
Health-Care Policy

Race/Ethnicity Mortality Disparity in Patients With De Novo Stage IV Breast Cancer: Effect of Medicaid Expansion

In a study reported in JAMA Oncology, Malinowski et al found that Medicaid expansion resulted in a reduction in the racial and ethnic disparities in mortality among patients with de novo stage IV breast cancer. As stated by the investigators, “Patients who are uninsured and belong to racial and...

Breast Cancer
Colorectal Cancer
Immunotherapy

Researchers Seek to Expand Immunotherapy Options for Patients With Advanced Breast and Colorectal Cancers

Two presentations given at the American Association for Cancer Research (AACR) Annual Meeting 2022 focused on promising strategies for making breakthrough immunotherapies work for more patients. Both studies report findings from clinical trials that advance a novel immunotherapy platform in...

Breast Cancer
Supportive Care

Longitudinal Patterns of Fatigue After Breast Cancer Diagnosis and Treatment

In an analysis from the French prospective CANTO study reported in the Journal of Clinical Oncology, Vaz-Luis et al identified three trajectory groups for the risk of severe global fatigue over time among women treated for breast cancer, consisting of a high-risk group, deteriorating group, and...

Breast Cancer

Risk of Cardiovascular Disease and Mortality in Women With Breast Cancer: The Pathways Heart Study

In an analysis from the prospective cohort Pathways Heart Study reported in the Journal of Clinical Oncology, Heather Greenlee, ND, PhD, and colleagues found that breast cancer survivors were at increased risk of cardiovascular disease and mortality compared with women without breast cancer, with...

breast cancer

Meenakshi Anurag, PhD, on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant

Meenakshi Anurag, PhD, of Baylor College of Medicine, discusses results from the ALTERNATE trial, which showed the combination of anastrozole plus fulvestrant was superior to either drug alone in inhibiting tumor proliferation in postmenopausal women with early-stage luminal B breast cancer (Abstract CT026).

Breast Cancer

Recurrent Noninvasive Breast Tumors May Not Always Be Related to the Primary Lesion

More than 10% of cases of recurrent ductal carcinoma in situ (DCIS) of the breast were de novo tumors that occurred independently of the primary lesion and had distinct genetic alterations, according to data presented by Kader et al during the American Association for Cancer Research (AACR) Annual...

Breast Cancer
Genomics/Genetics

Expert Point of View: Mark E. Robson, MD

“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...

Breast Cancer
Genomics/Genetics

OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer

The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk ­early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...

Breast Cancer

Having Metastatic Breast Cancer Has Led Me to Focus on What Matters

Nothing can really prepare you for cancer, but it helped that I have dedicated my life in service to others as a minister and advocate for social justice and health equity in breast cancer survivorship. Before my own breast cancer diagnosis in 2016, I had spent years as a volunteer for several...

Breast Cancer
Survivorship

Multilevel Factors Related to Changes in Body Adiposity in Black Survivors of Breast Cancer

In a study reported in the Journal of Clinical Oncology, Qin et al found that gains in body weight and body fat were common in a prospective cohort of Black breast cancer survivors. The researchers also identified factors associated with these changes. As stated by the investigators, “Unfavorable...

Breast Cancer
Survivorship

Study Identifies Decline in Annual Screening for Breast Cancer Survivors

New research published by Lowry et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography participation by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors. The researchers reviewed a nationwide commercial...

Breast Cancer

Study Finds Lumpectomy May Be as Effective as Mastectomy for Patients With Nonmetastatic Breast Cancer Younger Than 40

Young women with nonmetastatic breast cancer have similar survival rates whether they are treated with mastectomy or lumpectomy, despite tumors that are typically more aggressive and discovered at a later stage compared to their older counterparts. These findings were from a recent study examining...

Breast Cancer

Positive Lymph Nodes May Not Be an Indicator for Chemotherapy in Older Patients With Breast Cancer

Positive lymph node status may not be a reliable indicator of the need for adjuvant chemotherapy, and sentinel node biopsy may be unnecessary in older women with certain low-risk cancers, according to a new study presented by Nicholson et al at the American Society of Breast Surgeons 23rd Annual...

Breast Cancer
COVID-19

Study Finds COVID-19 Restrictions Delayed Breast Cancer Care at a Safety-Net Hospital

The 1-year local COVID-19 restrictions negatively impacted breast cancer stage at presentation, time to treatment, and time to surgery at an urban safety-net hospital, increasing the vulnerability of an already high-risk population. These findings were from a recent study presented by Kapp et al at ...

Breast Cancer

Prognostic Value of sTILs in Young Women With Node-Negative Triple-Negative Breast Cancer Who Did Not Receive (Neo)Adjuvant Systemic Therapy

In a Dutch retrospective study reported in the Journal of Clinical Oncology, de Jong et al found that higher levels of stromal tumor-infiltrating lymphocytes (sTILs) were associated with “excellent prognosis” in young women with node-negative triple-negative breast cancer who did not receive...

Breast Cancer
Supportive Care

Advances in Managing Cardiac Side Effects Associated With Breast Cancer Treatment

Guideline-directed medical therapy for the prevention and treatment of cardiotoxicity is improving quality of life and oncologic outcomes associated with breast cancer treatment, according to Jean-Bernard Durand, MD, FACP, FCCP, FACC, FHFSA, Professor of Medicine at The University of Texas MD...

Breast Cancer
Immunotherapy

DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer

As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...

Breast Cancer

Emerging Endocrine Therapies for the Management of Breast Cancer

Novel hormonal therapies for breast cancer could provide additional therapeutic options for patients with hormone receptor–positive breast cancer. The emerging landscape for these new agents was described at the 2022 Miami Breast Cancer Conference, sponsored by PER, by Aditya Bardia, MD, MPH,...

Breast Cancer
Survivorship

How Do Lifestyle and Cardiovascular Risk Factors Relate to Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors?

In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, and colleagues identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors, finding that both incidence of hospitalization and risk of...

Breast Cancer

PARP Inhibitors in the Treatment of Breast Cancer: What’s Next?

In patients with breast cancer tumors harboring BRCA1 and BRCA2 mutations, inhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as essential therapeutic agents. What more needs to be done to obtain even more benefit from these targeted agents? This question was tackled at the 2022 Miami...

Advertisement

Advertisement

Advertisement